BioSpace News Archive

SEngine Precision Medicine and Dana-Farber Cancer Institute today announced a collaboration to bring SEngine’s PARIS® Test to adult and pediatric patients with primary or metastatic solid-tumor central nervous system (CNS) cancers.

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it will present at the Jefferies London Healthcare Conference, which is taking place November 16-19, 2021.

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported third quarter 2021 financial results.

Histogen Inc. (NASDAQ: HSTO), today reported financial results for the third quarter ended September 30, 2021 and provided an update on its clinical pipeline and other corporate developments.

NeuroPace, Inc., today announced that it has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to study the company’s RNS® System in patients with drug-resistant idiopathic generalized epilepsy.

Femasys Inc., a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, announced financial results for the third quarter and nine months ended September 30, 2021 and provided a corporate update on the Company’s business and clinical programs.

Marrone Bio Innovations, Inc., an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the third quarter ended September 30, 2021.

Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, announced that Arcutis management will participate in an upcoming investor conference in November.

Hepion Pharmaceuticals, Inc. today announced that results from its Phase 2a ‘AMBITION’ NASH trial will be available as an e-poster at the Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases

Daré Bioscience, Inc. today reported financial results for the quarter ended September 30, 2021 and provided a company update.